Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

globenewswire.com
LUN LLY AMGN Included as a key player in the migraine market, but no specific details about its performance or pipeline are discussed. NVS Mentioned as a key company in both migraine and cluster headache markets, without specific performance details. TEVA Listed as a key company in the migraine market, but no specific positive or negative information is provided. ALLER BHVN Mentioned as a key company in the migraine market, but no specific details about its performance or pipeline are provided. DRREDDY ABBV IMPL ZSAN AXSM Identified as a key company in the migraine market, but the article offers no specific performance data or news. AEON Mentioned as a key company in the migraine market, but no specific details about its performance or pipeline are provided. IONS Listed as a key company in the migraine market, with no specific performance indicators or news mentioned. CHRC AZN Mentioned as a key company in the cluster headache market, but no specific performance details are provided. GSK Listed as a key company in the cluster headache market, but no specific performance indicators or news mentioned. WSTN

New York, USA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

The migraine therapeutics market is experiencing strong momentum as rising global prevalence, better diagnostic recognition, and expanding patient awareness steadily grow the treated population. Adoption of targeted therapies such as CGRP inhibitors and gepants continues to accelerate, driven by their superior tolerability and preventive benefits compared to older acute treatments. At the same time, telehealth expansion and wider access to specialty care are improving treatment initiation and follow-up, supporting a sustained shift toward guideline-based management. With a robust pipeline of biologics, oral agents, and device-based innovations, the competitive landscape is expected to broaden further, reinforcing long-term market growth potential.

DelveInsight’s ' Migraine Pipeline Insight 2025' report provides comprehensive global coverage of pipeline therapies for migraine across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the migraine domain.

Migraine Clinical Trial Analysis Summary

Request a sample and discover the recent advances in migraine drugs @ Migraine Pipeline Report

What is Migraine?

Migraine is a neurological disorder that causes intense pain and affects millions globally. It is the most prevalent neurological condition, significantly impacting brain function and influencing behaviors related to recurrent migraine episodes. The burden of migraine involves processes occurring before, during, and after an attack. Understanding migraine includes recognizing that normally non-painful stimuli, such as light, can intensify pain, and that migraine headaches can lead to widespread skin sensitivity. Advanced imaging studies have revealed changes in brain structure and function, offering more profound insights into the disease mechanisms. Migraines affect people worldwide and are often misdiagnosed as other types of headaches, such as tension-type headaches. Many sufferers may not receive an accurate diagnosis, effective treatment, or adequate support from family, friends, or colleagues. Treatment typically involves acute or abortive medications, while a smaller portion of patients use preventive therapies. Migraines remain a significant cause of global disability and suffering. Risk factors include both non-modifiable elements, such as genetics, gender, and age.

Find out more about migraine drugs @ Migraine Treatment

A snapshot of the Pipeline Migraine Drugs mentioned in the report:

Learn more about the emerging migraine therapies @ Migraine Clinical Trials

Recent Developments in Migraine Treatment Space

Scope of the Migraine Pipeline Report

Dive deep into rich insights for new migraine treatments, visit @ Migraine Drugs

Table of Contents

For further information on the migraine pipeline therapeutics, reach out @ Migraine Therapeutics

Related Reports

Migraine Epidemiology Forecast

Migraine Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted migraine epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Migraine Market

Migraine Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy’s Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, among others.

Cluster Headache Market

Cluster Headache Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical, among others.

Cluster Headache Clinical Trial Analysis Pipeline

Cluster Headache Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cluster headache companies, including Novartis AG, Zosano Pharma, Eli Lily and Company, AstraZeneca Plc., Autonomic Technologies, Inc., ElectroCore Medical LLC, GlaxoSmithKline Plc, Winston Pharmaceuticals Inc., Lundbeck Seattle BioPharmaceutical, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn